Danaher Co. (NYSE:DHR) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Danaher Co. (NYSE:DHR) by 3.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 5,097,986 shares of the conglomerate’s stock after acquiring an additional 148,251 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Danaher were worth $1,417,342,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of DHR. nVerses Capital LLC acquired a new stake in Danaher during the second quarter valued at approximately $25,000. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher during the second quarter valued at approximately $25,000. MidAtlantic Capital Management Inc. acquired a new stake in Danaher during the third quarter valued at approximately $40,000. Darwin Wealth Management LLC acquired a new stake in Danaher during the third quarter valued at approximately $55,000. Finally, MFA Wealth Advisors LLC acquired a new stake in Danaher during the second quarter valued at approximately $51,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analysts Set New Price Targets

DHR has been the topic of several research reports. Evercore ISI upped their price objective on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Raymond James cut their price objective on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. KeyCorp increased their price target on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. TD Cowen increased their price target on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Finally, Wells Fargo & Company initiated coverage on Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Stock Performance

Shares of NYSE DHR opened at $238.90 on Thursday. The stock has a fifty day moving average price of $256.00 and a two-hundred day moving average price of $259.66. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The firm has a market cap of $172.55 billion, a P/E ratio of 45.59, a PEG ratio of 4.37 and a beta of 0.85. Danaher Co. has a 1 year low of $215.68 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period last year, the company posted $2.02 EPS. Research analysts forecast that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is currently 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.